Source comparison
PT-141 vs Bremelanotide — What's the Difference?
PT-141 and bremelanotide are the exact same synthetic peptide. The cyclic heptapeptide that acts as a melanocortin receptor agonist with selective activity at MC3R and MC4R. The name divergence occurred in 2004 when Palatin Technologies transitioned the compou
This comparison does not assign a generated winner or score.
- PT-141 and bremelanotide are the exact same synthetic peptide. The cyclic heptapeptide that acts as a melanocortin receptor agonist with selective activity at MC3R and MC4R. The name divergence occurred in 2004 when Palatin Technologies transitioned the compound from Phase II clinical trials (where it was designated PT-141) to Phase III registration trials under the International Nonproprietary Name (INN) bremelanotide. The molecule itself. The seven-amino-acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Never changed. What changed was regulatory status, branding strategy, and eventually FDA approval in 2019 under the trade name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
- Our team at Real Peptides has synthesised PT-141 for research applications since 2018. The naming confusion creates sourcing errors we see consistently. Researchers assume PT-141 and bremelanotide represent different compounds with distinct pharmacological profiles, when in reality they're purchasing the same molecule under two commercial designations.
- What's the difference between PT-141 and bremelanotide?
- PT-141 and bremelanotide are identical. The same melanocortin receptor agonist peptide with no molecular variation. PT-141 is the original research code used during preclinical and early-phase clinical development; bremelanotide is the INN assigned when the compound advanced to Phase III trials and eventual FDA approval. The only substantive difference is regulatory classification: bremelanotide (Vyleesi) is FDA-approved as a prescription drug for HSDD, while PT-141 remains the designation used for non-approved research-grade material supplied by compounding facilities and peptide research suppliers.
- The Featured Snippet gives you the regulatory distinction. Here's the practical implication most sources skip. When you order PT-141 from a research supplier, you're receiving the same active peptide as branded Vyleesi, but without FDA batch-level oversight, without the pre-filled autoinjector delivery system, and at 70–85% lower cost per dose. The molecule is identical; the quality assurance infrastructure is not. Compounded PT-141 is synthesised by 503B facilities or sourced from international peptide manufacturers, then tested via HPLC and mass spectrometry for purity verification. But those tests are performed by the supplier, not by the FDA. This article covers the pharmacological mechanism both names describe, the sourcing and regulatory differences that create the price gap, and what preparation mistakes compromise peptide integrity before the first dose.